ClinicalTrials.gg
CompletedNCT06527742Updated Oct 29, 2026

Body Composition, Frailty, and Function in Rehabilitation

An observational study in Frailty, Stroke and Debility Due to Disease, sponsored by Changi General Hospital. Completed at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Changi General Hospital · Observational

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
345
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Frailty with a site in Singapore — 12 open to participants now, 13 under way, none of them phase 3. Frailty · Singapore.

Started
2024
with 2 others
Observational
7 of 28
3 open now
Registered
21st of 28
by date
Lead sponsor
3 of 28
Changi General Hospital

Among the 28 studies in Frailty with a site in Singapore, this one is one of 3 that started in 2024, is one of 7 observational ones, and was the 21st registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

12 of the 28 studies in Frailty with a site in Singapore are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Frailty with a site in Singapore, or all of them as a file.
02

Study summary

The investigators are investigating if body composition measures - in particular muscle mass, body fat, and something called the phase angle - are able to reliably predict functional outcomes for patients who are in an acute hospital for inpatient rehabilitation. The investigators also want to see if age and frailty affect these relationships.

Patients undergoing inpatient rehabilitation in our hospital will be monitored through a variety of frailty-specific tools, including strength and speed. The investigators will use a device called a body composition monitor (BCM) to record their body composition measurements. These will then be compared against their usual rehabilitation outcomes.

The investigators believe that there is a correlation between these measures and a patient's functional outcomes.

Read the detailed description

STUDY DESIGN This study is conceived as a prospective longitudinal follow-up cohort study tracking patients from admission (to the inpatient rehabilitation unit) till discharge. Ethics approval has been obtained. Trial registration will be performed. Reporting will conform to the STROBE guidelines.

STUDY POPULATION Consecutive purposive sample of all patients with stroke, deconditioning, lung disease, or amputation admitted to the CGH Rehabilitation Medicine unit.

CONDUCT OF STUDY The study will take place in the main inpatient ward of the CGH Rehabilitation Medicine unit. All patients transferred in for inpatient rehabilitation will undergo case note screening and physical examination as part of their routine post-transfer clerking. Patients fulfilling the inclusion and exclusion criteria will be approached for recruitment and enrolment within 48 work hours of transfer in to the unit. Baseline measurements will be collected, and they will undergo usual rehabilitation with the hospital's multidisciplinary team. Repeat measurements will also be collected upon discharge.

DATA COLLECTION

Patient data will be collected upon consent, including:

  1. Demographic data

    1. Age, ethnicity, and gender
    2. Handedness
    3. Occupation and employment status
    4. Highest education level
    5. Living arrangements and housing type
  2. Anthropometric data

    1. Height and body mass index (BMI)
    2. BIA measures of appendicular skeletal mass (ASM), phase angle (PhA), and percentage body fat (PBF) - measured twice and at least 15mins apart
  3. Functional data

    1. Premorbid mobility
    2. Activities of daily living by the Katz Index
    3. Functional Independence Measure (FIM)
  4. Clinical data

    1. Diagnosis group
    2. Charlson Comorbidity Index
    3. Intrinsic capacity measures per the Integrated Care for Older People screening guidance (ICOPE)
    4. Sarcopenia measured by the SARC-CalF tool
    5. Frailty measured by CFS and the FRAIL questionnaire
    6. Cognition by the Chinese version (28 marks) of the Mini-Mental State Examination (MMSE)
    7. Mood by the Hospital Anxiety and Depression Scale (HADS)
    8. Nutrition by the Mini Nutritional Assessment Short-Form (MNA-SF)
    9. Quality of Life by the 5-item EuroQOL 5-dimension questionnaire (EQ-5D-5L)
    10. Handgrip strength - measured twice
    11. Average medial gastrocnemius thickness by ultrasonography
    12. Routine blood test results (if done prior) of white cell count, C-reactive protein, albumin, iron saturation, and Vitamin D
  5. Physical performance data

    1. 10-metre walk test
    2. 5-times sit-to-stand test

On discharge, the following will be collected:

  1. Anthropometric data

    1. Updated body mass index (BMI)
    2. BIA measures of ASM, PhA, and PBF
  2. Clinical data

    1. Mood by the Hospital Anxiety and Depression Scale (HADS)
    2. Quality of Life by the 5-item EuroQOL 5-dimension questionnaire (EQ-5D-5L)
    3. Handgrip strength
  3. Physical performance data

    1. 10-metre walk test
    2. 5-times sit-to-stand test
  4. Administrative data a. Length of stay (by total duration and segmental stays in the acute and rehabilitation settings respectively) b. Confounders that could have affected rehabilitation adherence or participation (occurrence during stay of: i. Acute transient or irreversible cognitive dysfunction; ii. Mood dysfunction; iii. Moderate/severe pain; and iv. Low patient self-efficacy). All tools and questionnaires used are validated and included in many clinical guidelines both local and international.

SUBGROUP ANALYSIS

The investigators will perform subgroup analysis along 3 phenotypes:

  1. Admitting diagnosis group: "strokes", "deconditioning", "pulmonary", and "lower limb amputee"
  2. Frailty status: "frail", "at-risk", and "non-frail" patients as defined by CFS scores of ≥5, 4, and ≤3 respectively
  3. Age: "\<60yrs" and "≥60yrs"

STATISTICAL AND ANALYTICAL PLANS Descriptive statistics of patient demographic and clinical characteristics will be reported as number and percent for categorical data, mean ±SD for normally distributed data, and median and interquartile range (IQR) for non-normally distributed data. Intergroup comparisons will be made using the χ²/Fisher's exact test for categorical outcomes, unpaired t-test for normally distributed outcomes, and Mann-Whitney U-test for non-normally distributed outcomes. Multiple linear regression will be used to identify independent predictors of M-FIM at discharge, M-FIMeffectiveness, and handgrip strength. The assumption of linearity between the outcome and continuous predictors will be assessed using the Box-Tidwell test. Where there is evidence of non-linearity, the investigators will use a restricted cubic spline function with three knots at the 10th, 50th, and 90th percentiles, to model the relationship between continuous predictor and the outcome. Assumptions of homoscedasticity and normality of errors will be assessed using residual and Q-Q plots respectively. The investigators will check for multicollinearity using the variance inflation factor (VIF). Beta coefficients with corresponding 95% confidence intervals (CIs) will be reported. Statistical tests will be two-sided with a 0.05 significance level. All statistical analyses will be conducted using IBM SPSS Statistics version 23.0 (IBM Corp, Armonk, NY, USA). No interim analysis is necessary as the study is not conceptualised as a randomised controlled trial.

WITHDRAWAL FROM THE STUDY Subjects may withdraw voluntarily from participation in the study at any time, including after discharge, with no prejudice to their clinical care or outpatient follow-up. Their data will be removed from the electronic records, and the hardcopy data collection form will be physically destroyed. Their withdrawal will be reported in the STROBE flowchart subsequently.

DISCONTINUATION OF THE STUDY The study may be discontinued for any of the following reasons.

  1. Adverse event or serious adverse event related to data collection or study conduct, which implicates safety of subsequent recruits
  2. Breakdown of the BIA machine with no cost-effective repair or replacement option available
  3. Other unforeseen circumstances In the event of study discontinuation, the investigators will inform the CIRB accordingly and the study team will evaluate the incomplete data to determine if there is sufficient scholarly merit remaining to justify write-up and publication.

SAFETY MONITORING PLAN Patients will be under the care of a trained study team member during clinical measurements, who will be expected to safely operate the different measuring devices (dynamometer and BIA machine). They will be monitored for pain and discomfort during use of the devices. Other clinical deteriorations will be managed routinely. Data will be reviewed on a monthly basis by an appointed co-investigator for integrity as well as completion. This includes screening and recruitment figures, as well as demographic, anthropometric, and clinical measurements, as well as functional outcomes. Data safety will be through lock-and-key storage of physical documents as well as access-restricted, password-protection for electronic data, which can only be viewed on the hospital's intranet-facing devices.

DATA ENTRY AND STORAGE Demographic data will be collected from patients' electronic medical records. Anthropometric and clinical measurements will be collected physically. All records will be recorded in a hardcopy data collection form to be filed in the Investigator Site File (ISF) that is stored under lock-and-key in the Research Office. All data will be transcribed electronically into REDCap which is hosted on the hospital's intranet and is access-restricted as well as password-protected. Only study team members (including the clinical research co-ordinator) will have access to the data. Data will be de-identified prior to analysis by the statistician. All data will be kept for 7 years post-completion or post-publication, whichever is later. Following that, electronic data will be deleted and all paper records will be physically destroyed.

DATA QUALITY ASSURANCE All data will be collected by a small pre-defined group of trained medical doctors and clinical research co-ordinators with medical backgrounds. All study team members will be pre-trained and briefed on the use of the clinical measurement devices. Anthropometric measurements of height, weight, and BMI will be collected by the inpatient ward nurses during patients' hospitalisation. FIM is documented on a weekly basis by the inpatient clinical teams after discussion with the multidisciplinary team. All study team members will have previous training and experience in accessing the patients' electronic medical records

ETHICAL CONSIDERATIONS This study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the Good Clinical Practice and the applicable regulatory requirements. The principal investigator is responsible for informing the CIRB of any amendments to the protocol or other study-related documents, as per local requirement.

INFORMED CONSENT Patients will be referred by the primary team. Eligible patients would then be approached for consent while they are inpatient, within 48 work hours of transfer in to the unit. All study team members would be trained and hence eligible for consent-taking. Consent will be taken physically and in writing. Risks and benefits of participation will be clearly explained. Patients will be given ample time to make a decision and/or decline with no impact on their standard of clinical care. If a family member's presence is requested or deemed necessary but they cannot be present at the bedside, the investigators will consider remote consent-taking per the cluster guidance document on "Guidance on Remote Consent Process and Documentation for Research. A witness will not be required for all consent-taking as the study does not involve invasive procedures. Upon enrolment into the study, a note will be entered into the patient's electronic medical record. For non-English speakers, the investigators will use appropriate translation (in Mandarin, Malay, or Tamil) with the assistance of a translator where necessary. A witness will be present. Patients with cognitive impairment may be recruited as this may be a sequela of their acute stroke, or they may have underlying impairments. The study team member assessing for cognitive impairment would have been satisfactorily trained prior. They will be treated as vulnerable population if unable to participate in the consent-taking and research process, as per the Mental Capacity Act (2008). The investigators do not foresee the recruitment of other special populations such as children, prisoners, or other vulnerable individuals. In obtaining and documenting informed consent, the investigator should comply with the GCP guidelines and to the ethical principles that have their origin in the Declaration of Helsinki.

03

Conditions studied

  • Frailty
  • Stroke
  • Debility Due to Disease

Keywords

  • Stroke
  • Frailty
  • Sarcopenia
  • Deconditioning
  • Body fat
  • Skeletal muscle mass
  • Phase angle
  • Bioimpedance analysis
  • Body composition measurement
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients over the age of 21 years admitted to the Changi General Hospital Rehabilitation Medicine unit in Singapore, up to a target sample size of 345 patients. There are no race-based subject restrictions. There will not be any gender-based or minority-based exclusion.

Our patients come from other departments such as the Acute Stroke Unit and General Surgery, and have various medical backgrounds as well as medical conditions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Transferred under the Rehabilitation Medicine service for post-acute rehabilitation
  2. Rehabilitation diagnosis of:

    1. Stroke with motor weakness (modified Rankin scale 1-5), or
    2. Deconditioning (from sepsis, post-ICU admission, heart failure, falls, musculoskeletal conditions with or without pain, or other conditions), or
    3. Pulmonary rehabilitation (with or with long-term oxygen therapy), or
    4. Lower limb amputees (transtibial or transfemoral)
  3. Medically stable
  4. Able to understand English consent form or suitably-translated document, or have a family member/legally-authorised representative who is able to do so and willing to provide consent

Exclusion criteria

Exclusion Criteria:

  1. Pacemaker or implantable defibrillator in-situ
  2. Medical devices or surgical implants that will interfere with BIA measurement per the manufacturer's guidelines
  3. Abnormal fluid status (overloaded or depleted) at the point of screening
  4. Cognitive or physical inability to tolerate sitting/lying still for 2mins (for BIA measurement)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
345 participants (actual)
Target follow-up
2 Months
Patient registry
Yes

Groups and cohorts

  • Eligible patients

    Consecutive purposive sample of all patients with stroke, deconditioning, lung disease, or amputation admitted to the Changi General Hospital Rehabilitation Medicine unit All patients transferred in for inpatient rehabilitation will undergo case note screening and physical examination as part of their routine post-transfer clerking. Patients fulfilling the inclusion and exclusion criteria will be approached for recruitment and enrolment within 48 work hours of transfer in to the unit. Baseline measurements will be collected, and they will undergo usual rehabilitation with our multidisciplinary team. Repeat measurements will also be collected upon discharge.

06

What researchers measure

Primary outcomes

  1. M-FIM

    Motor component of the Functional Independence Measure

    Time frame: Baseline at recruitment, and upon discharge from the inpatient rehabilitation unit which is an average of 2 weeks later

Secondary outcomes

  1. M-FIM effectiveness

    M-FIM effectiveness is a derivative of the M-FIM value which has been corrected for the ceiling effect that the M-FIM value sometimes encounters in patients with higher baseline FIM scores. This is a single outcome value with a single unit of measure.

    Time frame: Upon discharge from the inpatient rehabilitation unit which is an average of 2 weeks later

  2. Grip strength

    Handgrip strength measured in kg

    Time frame: Baseline at recruitment, and upon discharge from the inpatient rehabilitation unit which is an average of 2 weeks later

07

Study locations

1 site
  • Changi General Hospital
    Singapore, Singapore 529889, Singapore
08

References and documents

Individual participant data

Plan to share: No — Data is protected under the SingHealth Data Protection Policy which is compliant to the Singapore Personal Data Protection Act 2012

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Dec 2025, 12 months.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's 12 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Sep 2025 → Dec 2025 and completion Sep 2025 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Jul 30, 2024
StartActual
Dec 9, 2024
Primary completionActual
Dec 12, 2025was Sep 2025
CompletionActual
Dec 12, 2025was Sep 2025
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Sites
1 site added, 1 site removed
Show site
  • Changi General Hospital · Singapore, Singapore
Show 1 removed
  • Changi General Hospital · Singapore, Singapore
Oct 29, 2026
Primary completion
Sep 2025→Dec 12, 2025 (actual)
Oct 29, 2026
Study completion
Sep 2025→Dec 12, 2025 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Changi General Hospital · Singapore, Singapore
    Show 1 removed
    • Changi General Hospital · Singapore, Singapore
    Primary completion Sep 2025→Dec 12, 2025 (now actual)
    Study completion Sep 2025→Dec 12, 2025 (now actual)
    + 5 other changes: index terms, identifiers, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06527742
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Dec 9, 2024
Primary completion
Dec 12, 2025
Completion
Dec 12, 2025
Last update
Oct 29, 2026

Study contacts

Edmund JR Neo, MBBS
principal investigator · Singapore Health Services Pte Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion